TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21989146

Group type: EXPERIMENTAL
Intervention: LOAD-10 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 10 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LOAD-7 therapy (levofloxacin 250 mg, omeprazole 40 mg, nitazoxanide 500 mg twice daily, doxycycline 100 mg) for 7 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combined LOAD therapies
Number of subjects: 180

Group type: COMPARATOR
Intervention: LAC therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg) for 10 days
Number of subjects: 180
Study: 18087212

Group type: EXPERIMENTAL
Intervention: bi-layer composite membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: bi-layer composite membrane with moisturizer
Number of subjects: 18

Group type: COMPARATOR
Intervention: bi-layer composite membrane after moisturizer application
Number of subjects: 18
Study: 16470745

Group type: EXPERIMENTAL
Intervention: Paclitaxel, 200 mg/m² IV, every 21 days for a minimum of four cycles
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 15347717

Group type: EXPERIMENTAL
Intervention: V/Q lung scintigraphy in SPECT technique
Number of subjects: 83

Group type: COMPARATOR
Intervention: Planar V/Q scintigraphy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Multislice spiral CT
Number of subjects: 83
Study: 11588321

Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus before the lesion was crossed with guidewire and 0.125 micro. kg(‐1). min(‐1) infusion for 12 hours)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 151
Study: 9849555

Group type: EXPERIMENTAL
Intervention: Protocol A (without immediate access to laboratory tests)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protocol B (with immediate access to laboratory tests)
Number of subjects: 0
Study: 7862710

Group type: EXPERIMENTAL
Intervention: Naloxone (0.01, 0.1, 1.0 mg/70 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (1.0, 3.0, 10 mg/70 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% in oxygen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100% oxygen placebo
Number of subjects: 0
Study: 2512175

Group type: EXPERIMENTAL
Intervention: Rhein (diacetyl‐rhein 50 mg b.d. for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31979255

Group type: EXPERIMENTAL
Intervention: FMS‐based afterschool program (n = 20)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional afterschool program (n = 11)
Number of subjects: 31
Study: 31404683

Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Real Dipyrone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo Acupuncture
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo Dipyrone
Number of subjects: 56
Study: 28323084

Group type: EXPERIMENTAL
Intervention: HospBLS
Number of subjects: 122
Study: 26562297

Group type: EXPERIMENTAL
Intervention: Group A (labeled as 'person'/'child with epilepsy')
Number of subjects: 425

Group type: COMPARATOR
Intervention: Group B (labeled as 'epileptic'/'epileptic child')
Number of subjects: 425
Study: 22820956

Group type: EXPERIMENTAL
Intervention: Postbariatric abdominoplasty (20 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (12 patients waiting for abdominoplasty)
Number of subjects: 32
Study: 20947068

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 18948149

Group type: EXPERIMENTAL
Intervention: Crime context with accomplices
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neutral context with accomplices
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Crime context with innocents
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neutral context with innocents
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study: 17170650

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15220879

Group type: EXPERIMENTAL
Intervention: Low-contact dynamic compression plating (LC-DCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic compression plating (DCP)
Number of subjects: 0
Study: 11417145

Group type: EXPERIMENTAL
Intervention: Rapid Self-Hypnosis (RSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypnosis Induction Profile (HIP)
Number of subjects: 0
Study: 9248252

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 14
Study: 8257478

Group type: EXPERIMENTAL
Intervention: 5'-MTHF (50 mg/day p.o.)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Trazodone (100 mg/day p.o.)
Number of subjects: 96
Study: 3582469

Group type: EXPERIMENTAL
Intervention: Urapidil infusion at 10 mg/h for 4 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urapidil infusion at 2.5 mg/h for 4 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urapidil infusion at 5 mg/h for 4 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urapidil infusion at 10 mg/h followed by a 60 mg capsule after 2 h
Number of subjects: 12
Study: 29360843

Group type: EXPERIMENTAL
Intervention: Speaking (counting loudly and repeatedly from one to ten)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking (mentally counting repeatedly from one to ten)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Listening (listening to verbal counting from one to ten)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no perturbation)
Number of subjects: 0
Study: 26135499

Group type: EXPERIMENTAL
Intervention: E-learning module
Number of subjects: 39

Group type: COMPARATOR
Intervention: Near-peer tutorial
Number of subjects: 39
Study: 26161535

Group type: EXPERIMENTAL
Intervention: ALMANACH
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 1465
Study: 23176073

Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline
Number of subjects: 109

Group type: COMPARATOR
Intervention: 1.5 mg pramipexole
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline and 1.5 mg pramipexole
Number of subjects: 109
Study: 20885016

Group type: EXPERIMENTAL
Intervention: Pentazocine 0.5 mg·kg(‐1) 5 min prior to fentanyl
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Normal saline (Group II)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Normal saline (Group I)
Number of subjects: 277
Study: 18979582

Group type: EXPERIMENTAL
Intervention: Fiber mixture
Number of subjects: 97

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 97
Study: 16492133

Group type: EXPERIMENTAL
Intervention: Computer-based program to teach facial affect identification
Number of subjects: 10
Study: 14561116

Group type: EXPERIMENTAL
Intervention: Event-related brain potentials assessing attentional processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related brain potentials assessing working-memory processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related brain potentials assessing attention to gender
Number of subjects: 0
Study: 10765090

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 8776692

Group type: EXPERIMENTAL
Intervention: Standard osmolality feeding (1200 mOsmol/L)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High osmolality feeding (1700 mOsmol/L)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Overall results for all lines
Number of subjects: 36
Study: 1626958

Group type: EXPERIMENTAL
Intervention: Isotretinoin (approximately 0.14 mg/kg per day for 3 years)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 6437509

Group type: EXPERIMENTAL
Intervention: Loperamide 0.8 mg/kg/24 h
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Loperamide 0.4 mg/kg/24 h
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo plus oral rehydration therapy
Number of subjects: 315
Study: 31348840

Group type: EXPERIMENTAL
Intervention: HEMOBLAST (HB) hemostatic powder
Number of subjects: 24
Study: 29421020

Group type: EXPERIMENTAL
Intervention: High-flow oxygen (10-15 L/min)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 124
Study: 26760454

Group type: EXPERIMENTAL
Intervention: Enhanced contact protocol for 12 months
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1838
Study: 24412053

Group type: EXPERIMENTAL
Intervention: miR-10b
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-21
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-7
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-31
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-101
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-137
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-222
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: miR-330
Number of subjects: 60

Group type: COMPARATOR
Intervention: miR-34a
Number of subjects: 60
Study: 21895939

Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) instillation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 36
Study: 20970847

Group type: EXPERIMENTAL
Intervention: Aspirin (≥75 mg daily)
Number of subjects: 14033

Group type: EXPERIMENTAL
Intervention: Aspirin (75-300 mg daily)
Number of subjects: 14033

Group type: COMPARATOR
Intervention: Aspirin (30 mg vs 283 mg daily)
Number of subjects: 14033
Study: 17284755

Group type: COMPARATOR
Intervention: Control group: 30 g dry weight of an iron-fortified cereal porridge and a separate dose of an aqueous multivitamin (MV) supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnSuppl group: same porridge and MV with 3 mg Zn added to the supplement dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnFort group: porridge with added zinc (150 mg/kg dry weight) and MV without zinc
Number of subjects: 0
Study: 16086129

Group type: EXPERIMENTAL
Intervention: Media-mediated events in elderly healthy people
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media-mediated events in younger normal subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normative procedure applied to subjects with probable Alzheimer's disease or mild cognitive impairment
Number of subjects: 0
Study: 12212714

Group type: EXPERIMENTAL
Intervention: Peer sexual health intervention (1 hour and 45 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer water purification intervention (1 hour)
Number of subjects: 0
Study: 11531750

Group type: EXPERIMENTAL
Intervention: Non-contrast enhanced helical CT
Number of subjects: 242

Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 242
Study: 9049794

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control electric toothbrush
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional soft manual toothbrush (Jordan)
Number of subjects: 111
Study: 8457038

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms twice daily for 14 days)
Number of subjects: 30
Study: 3469982

Group type: EXPERIMENTAL
Intervention: Prognostic indices (age, blood pressure, white cell count, blood urea, serum calcium, aspartate aminotransferase, lactate dehydrogenase, blood glucose, arterial blood pH and PO2)
Number of subjects: 100
Study: 31629353

Group type: EXPERIMENTAL
Intervention: LOW carbohydrate availability during low-intensity training (LIT) sessions
Number of subjects: 11

Group type: COMPARATOR
Intervention: HIGH carbohydrate availability during low-intensity training (LIT) sessions
Number of subjects: 11
Study: 29189275

Group type: EXPERIMENTAL
Intervention: US-assisted LSGB with 10 mL of 0.25% levobupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: FL-guided LSGB with 10 mL of 0.25% levobupivacaine
Number of subjects: 50
Study: 27346859

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 16

Group type: COMPARATOR
Intervention: Follicular phase
Number of subjects: 16
Study: 24717789

Group type: EXPERIMENTAL
Intervention: GSK2190915 200 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 23685330

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD), inhaler used when feeling the urge to smoke
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo, inhaler used when feeling the urge to smoke
Number of subjects: 24
Study: 20616088

Group type: EXPERIMENTAL
Intervention: Second cohort signers (acquired language in a more complex form)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Second cohort signers
Number of subjects: 2

Group type: COMPARATOR
Intervention: First cohort signers
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Consistent linguistic marking of left-right relations
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Consistent marking of ground information
Number of subjects: 2
Study: 18441680

Group type: EXPERIMENTAL
Intervention: Thiotorpium bromide (TB) 18 mcg/day for one year, almitrine 10 mg/kg/day for 3 months, and an 8 week course of pulmonary rehabilitation (PR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Thiotorpium bromide (TB) and pulmonary rehabilitation (PR)
Number of subjects: 39
Study: 16619217

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA) by nurses
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Lugol's Iodine (VILI) by nurses
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA) by physicians
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Lugol's Iodine (VILI) by physicians
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Pap cytology
Number of subjects: 1528
Study: 15029983

Group type: EXPERIMENTAL
Intervention: 50 mg oral methadone tablet
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 5 mg sublingual buprenorphine tablet
Number of subjects: 204

Group type: COMPARATOR
Intervention: 50 mg oral naltrexone
Number of subjects: 204
Study: 10966839

Group type: EXPERIMENTAL
Intervention: GP‐C (glycosaminoglycan polypeptide association complex) 2 ml intramuscularly, 10 courses over 5 years (15 injections per course, twice weekly)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: GP‐C
Number of subjects: 394
Study: 8979741

Group type: EXPERIMENTAL
Intervention: 2.9 km/day (3,000 walking steps/day) (hypokinetic subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 14.6 km/day (10,000 running steps/day) (control subjects)
Number of subjects: 20
Study: 1335393

Group type: EXPERIMENTAL
Intervention: KCl (100 mmol)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NaCl (100 mmol)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: KCl (0.75 mmol/kg infused over 2 h)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: KHCO3 (1 mmol/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: KCl (1 mmol/kg)
Number of subjects: 21
Study: 29713728

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 2004
Study: 26430128

Group type: EXPERIMENTAL
Intervention: Lecture training method
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Paper-based training method
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Computer training method
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 24581929

Group type: EXPERIMENTAL
Intervention: Absolute frequency and/or percentage information
Number of subjects: 2807

Group type: EXPERIMENTAL
Intervention: Relative frequency information
Number of subjects: 2807

Group type: COMPARATOR
Intervention: No efficacy information
Number of subjects: 2807
Study: 22051419

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion at a dose of 0.1 μg/kg/min with an initial bolus (12 μg/kg for 10 minutes) after anesthesia induction (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP) one day before surgery (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prophylactic IABP one day before surgery and levosimendan infusion (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 90
Study: 21138627

Group type: EXPERIMENTAL
Intervention: Without anti-viral therapy (study group)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Lamivudine therapy (control group)
Number of subjects: 177
Study: 18207017

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation
Number of subjects: 31290

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished women (MUAC <23.5 cm)
Number of subjects: 31290

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anaemic women (Hb <110 g/L)
Number of subjects: 31290

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished women
Number of subjects: 31290

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anaemic women
Number of subjects: 31290

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) supplementation
Number of subjects: 31290
Study: 15985134

Group type: EXPERIMENTAL
Intervention: L‐aspartate and L‐glutamate-enriched cardioplegia (13 mmol/L)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (cardioplegia including only potassium and sodium bicarbonate)
Number of subjects: 22
Study: 12544752

Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation (TCES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active placebo device
Number of subjects: 20
Study: 10391395

Group type: EXPERIMENTAL
Intervention: Metformin (250 mg three times daily for 12 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8683251

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) / vincristine, carmustine (BCNU), doxorubicin, and prednisone (VBAP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (conventional chemotherapy)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Early high-dose therapy (HDT)
Number of subjects: 77
Study: 1706505

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: VVI pacing (in crossover study)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preimplant predictive value for VVI pacing success
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preimplant predictive value for VVI pacing failure
Number of subjects: 60
Study: 6144125

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg, 3 mg, and 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propericiazine 10 mg and 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propericiazine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30681754

Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg (open-label phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching from placebo to opicapone
Number of subjects: 0
Study: 30383670

Group type: EXPERIMENTAL
Intervention: Microecological preparation supplementation
Number of subjects: 0
Study: 27174665

Group type: EXPERIMENTAL
Intervention: Carescapes intervention
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study: 25036712

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label levodopa treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study: 22933023

Group type: EXPERIMENTAL
Intervention: Hypoxia (Fi(O2) = 0.13)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normoxia (NOR)
Number of subjects: 6
Study: 20153684

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium (CMC), 0.5% (Cellufresh)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400, 2.5% and sodium hyaluronate (Blink Intensive Tears)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HP Guar 0.18% (Systane)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 17216895

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - music
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - kaleidoscope
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - guided imagery
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study: 12614797

Group type: EXPERIMENTAL
Intervention: Stented Perimount bioprosthesis (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stentless Prima Plus bioprosthesis (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (stented and stentless)
Number of subjects: 40
Study: 10869576

Group type: COMPARATOR
Intervention: Forced-choice recognition test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yes-no recognition test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0
Study: 9199818

Group type: EXPERIMENTAL
Intervention: rt-PA, 100 mg over 2 h (Group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: rt-PA, 0.6 mg/kg, maximum dose 50 mg, over 15 min (Group B)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 1350485

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol 200 mg
Number of subjects: 0
Study: 3900392

Group type: EXPERIMENTAL
Intervention: Amflutizole 500 mg dosage
Number of subjects: 29
Study: 31630511

Group type: EXPERIMENTAL
Intervention: Whey Protein Nutritional Drink (WPND)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Apple Juice (AJ)
Number of subjects: 19